Slide 1: Second Quarter 2022 Operating & Financial Results Conference Call
Second Quarter 2022 Operating & Financial Results Conference Call / Webinar August 8th, 2022 4:30 PM Eastern Time NASDAQ :LTRN
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents, Speakers, Host
Contents Speakers Host 01 Introduction 02 Q2 2022 Highlights Panna Sharma Chief Executive Officer, President and Director 03 Financial Highlights 04 Q&A David Margrave Nicole Leber Chief Financial Officer Investor Relations
Slide 4: Lantern Pharma
Lantern Pharma Leveraging A.I. to reduce oncology drug development costs and improve the likelihood of success Abundance of data Proprietary A.I. platform RADR® Accelerated timeline and reduced cost Second Quarter 2022 Earnings 3
Slide 5: Lantern Pharma's CNS Indications Have Significant Stand-alone Value
Lantern Pharma’s CNS Indications Have Significant Stand-alone Value Lantern’s CNS indications represent market potential of over $4 Billion USD GBM ATRT & Pediatric CNS Brain Mets Other High-Grade Gliomas Estimated Estimated Estimated Estimated $1.5-2 Billion $0.2 Billion $2+ Billion $0.5 Billion Ma
Slide 6: Second Quarter 2022 Highlights
Second Quarter 2022 Highlights Harmonic™ Trial RADR® Expansion • Submitted IND amendment including a finalized • RADR® has surpassed 21 billion datapoints. • Significant improvements to machine learning algorithms clinical study protocol to the FDA in April 2022 for Phase 2 trial. & modeling tools.
Slide 7: Harmonic Clinical Trial – Phase 2 Trial for LP-300
Harmonic™ Clinical Trial – Phase 2 Trial for LP-300 The Harmonic Trial for LP-300 Launched in Q2 and Will Begin Enrolling Patients in Q3 Harmonic™ is a clinical trial for never smoker patients with relapsed NSCLC • Harmonic™ trial will assess the effect of LP-300 in combination with standard of care
Slide 8: LP-300 with Chemotherapy Shows a Doubling of Overall and Two Year Survival
Harmonic™ Clinical Trial – Phase 2 Trial for LP-300 LP-300 with Chemotherapy Shows a Doubling of Overall and Two Year Survival 2 Year Survival Overall Survival Never Smokers and NSCLC What is a “Never Smoker”? 125% median survival increase 91% median survival increase CDC defines a never smoker as a
Slide 9: Harmonic Trial Will Provide Unique Longitudinal Assessment of Liquid Biopsies
Harmonic™ Clinical Trial – Phase 2 Trial for LP-300 Harmonic™ Trial Will Provide Unique Longitudinal Assessment of Liquid Biopsies of Never Smokers with NSCLC • The patient samples will be assessed Liquid biopsies will be for both genomic and transcriptomic taken from Harmonic™ changes & response cl
Slide 10: Progress of LP-184 Towards Trials
Progress of LP-184 Towards Trials LP-184 IND Filing Anticipated in Q1 2023 with Multiple Trial Launches in Q2 2023 01. Phase 1 Clinical Trial for LP-184 in Solid Tumors Genomically defined pancreatic, bladder cancers, and other solid tumors Targeted for Q4 2022 / Q1 2023 Targeted for Q2 2023 Complet
Slide 11: Progress of LP-284 towards trials
Progress of LP-284 towards trials LP-284 IND Filing Anticipated in Q1 2023 With Trial Launch in 2023 01. Phase 1 Clinical Trial for LP-284 in non-Hodgkin’s B-cell Lymphomas Targeted for Q1 2023 Targeted for Q1-Q2 2023 Targeted for Q2-Q3 2023 Complete the IND Phase 1 Expected Timeline IND filing enab
Slide 12: RADR Has Surpassed 21 Billion Datapoints and Undergone Significant Improvements
RADR® Has Surpassed 21 Billion Datapoints and Undergone Significant Improvements Future Goals For A.I. Platform 1. Focus on automation of data acquisition 2. Improve data interface to other analytical tools & containers 3. Improve tagging of metadata and algorithms 4. Enter into additional value-bas
Slide 13: Lantern Will Host a KOL Webinar Sept. 22nd for Childhood Cancer Awareness Month
Lantern Will Host a KOL Webinar Sept. 22nd for Childhood Cancer Awareness Month Key Opinion Leader (KOL) Webinar on LP-184, LP-284, and the treatment of pediatric cancer Lantern Collaboration Partner Peter Houghton Ph.D. Professor & Principal Investigator at Greehey Children's Cancer Research Instit
Slide 14: New Preclinical Data will Be Presented at Multiple Scientific Conferences in Q3/Q4
New Preclinical Data will Be Presented at Multiple Scientific Conferences in Q3/Q4 September October MicroCap Rodeo Presents: AACR 2022 Annual Meeting Windy City Roundup 2022 13 12 September 13th -16th , 2022 October 12th – 13th , 2022 in Boston, MA in Chicago, IL SOHO 2022 Annual Meeting ThinkEquit
Slide 15: Financial Update Q2 2022
Financial Update Q2 2022 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended June 30, (unaudited) (unaudited) 2022 2021 6/30/2022 12/31/2021 Operating expenses: Cash, Cash Equivalents & $ 62,149,497 $ 70,725,447 Marketable Securities General and administrative $ 1,405
Slide 16: Key Corporate Objectives and Milestones
Key Corporate Objectives and Milestones ● 2022 Objectives and Milestones Advance enrollment of The Harmonic™ Trial – Phase 2 clinical trial for LP-300 in NSCLC & increase patient & clinician awareness ● Assess LP-100 clinical development in conjunction with PARPi ● Finalize IND-Enabling studies & cl
Slide 17: Nasdaq: LTRN
www.lanternpharma.com @LanternPharma Nasdaq: LTRN IR Contact: IR@lanternpharma.com 1-972-277-1136 connect with us!